Year Founded
2010
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Stem cell therapyGene therapyAutologous cell therapyNatural killer cell therapy (NK cell therapy)CAR T cell therapy (CAR-T)

Allife Medicine General Information

Has secured clinical approvals for iPSC-derived cellular drugs and CAR-NK cell therapy drugs. ALF201 (EPC therapy) is in Phase I trials for acute ischemic stroke, showing promise in extending treatment window beyond traditional thrombolytic therapy.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

ALF201
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Allife Medicine's pipeline data

Book a demo

Key Partnerships

Tian Tan Hospital, Beijing Cancer Hospital, Tongren Hospital

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Allife Medicine Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Allife Medicine's complete valuation and funding history, request access »